QC Kinetix (Springs Medical)
- PRP Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
- Stem Cell Therapy
Louisville, KY
Louisville supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through University of Louisville Hospital, Norton Healthcare, and Baptist Health, and stem cell practice in the area spans the Highlands, St. Matthews, and the Medical District. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Kentucky regulates physician practice through the Kentucky Board of Medical Licensure. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The 3 Louisville clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Kentucky Board of Medical Licensure licensure checks.
Regulatory context
Kentucky cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Kentucky for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Kentucky's regulatory environment relies on federal law and the Kentucky Medical Practice Act.
The FDA has corresponded with Kentucky providers offering cellular therapies, and warning letters have been issued to regional clinics with operations in or near Kentucky. The Kentucky Board of Medical Licensure has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Kentucky Attorney General's Office of Consumer Protection can pursue deceptive marketing under the Kentucky Consumer Protection Act. Kentucky has not produced a high-profile federal injunction specific to its stem cell clinics, but enforcement risk tracks federal action.
Explore related care